Tadalafil
Product Images NDC 50090-5724

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-5724). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905724)

Tadalafil 5 mg bottle label from A-S Medication Solutions. The label includes the product number, lot number, and dosage form as film-coated tablets. Storage instructions specify keeping the product between 68 to 77 degrees Fahrenheit. The bottle contains 90 tablets and includes a QR code along with the NDC 50090-5724-0.*

FDA Label Image

Fig1 (Tadalafil Figure 1)

A set of four line graphs showing blood pressure differences (mmHg) between Tadalafil and placebo over time (hours). The graphs depict changes in standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP from 0 to 96 hours.*

FDA Label Image

Fig (Tadalafil Figure 2)

A dual-line graph depicting changes in systolic blood pressure (mmHg) over 24 hours post-dose. The top graph shows standing systolic blood pressure, comparing Tadalafil 20 mg with doxazosin 8 mg against placebo with doxazosin 8 mg. The bottom graph shows supine systolic blood pressure under the same conditions over time.*

FDA Label Image

Fig (Tadalafil Figure 3)

A line graph showing the changes in systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil or placebo combined with 8 mg doxazosin, measured at 08:00 and 20:00. The graph compares four different treatment groups, with systolic blood pressure on the vertical axis and time after administration on the horizontal axis.*

FDA Label Image

Fig (Tadalafil Figure 4)

A pharmacokinetic curve showing plasma tadalafil concentration (μg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The plot includes error bars indicating variability at measured time points.*

FDA Label Image

Fig (Tadalafil Figure 5)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment comparing Tadalafil 5 mg tablets and placebo. The graph indicates a greater reduction in symptoms for patients taking Tadalafil versus placebo, with scores plotted at 0, 4, 8, and 12 weeks. A significance level of p<0.01 is noted.*

FDA Label Image

Fig (Tadalafil Figure 6)

A line graph comparing changes from baseline in IPSS total score over treatment duration (weeks) between Tadalafil Tablets 5 mg and placebo. The graph shows greater improvement with Tadalafil, with statistical significance indicated at some points (p<0.01).*

FDA Label Image

Fig (Tadalafil Figure 7)

A line graph titled 'Weeks of Therapy' showing Least Squares Mean Change from Baseline over 26 weeks. It compares Tadalafil/Finasteride and Placebo/Finasteride groups, with data points at weeks 0, 4, 12, and 26. Statistical significance indicators (a p<0.001, b p<0.05) are included, along with a dashed line representing Least-Squares Treatment Difference.*

FDA Label Image

Fig (Tadalafil Figure 8)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil Tablets 5 mg and placebo. The x-axis indicates treatment duration in weeks, and the y-axis shows change scores. The Tadalafil group shows a greater reduction in IPSS scores than placebo, with statistically significant differences (p<0.01).*

FDA Label Image

Stru (Tadalafil Structure)

Chemical structure diagram of tadalafil showing its molecular arrangement with rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.